SCHEMBL445504

SCHEMBL445504

CCOC(=O)c1cccc(N=C=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
HPGD P15428 2/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.47
MEP1B Q16820 1/20 0.47
ALDH1A1 P00352 2/20 0.47
TSHR P16473 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
LMNA P02545 1/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30427003 1.00 CYP4F2 (0.50) CYP4F2CYP4A11CA12CA1CA2
SCHEMBL7529742 0.90 CYP4F2 (0.42) CYP4F2CYP4A11CA12CA1CA2
SCHEMBL5558418 0.87 CYP4F2 (0.49) CYP4F2CYP4A11CA12CA1CA2
SCHEMBL11557416 0.86 CYP1A2 (0.50) HPGDTP53TSHRSMN1; SMN2LMNA
SCHEMBL8424695 0.84 CYP3A4 (0.38) CYP4F2CYP4A11HPGDTP53POLB
SCHEMBL9420554 0.84 SMN1; SMN2 (0.44) CYP4F2CYP4A11CA1CA2TSHR
SCHEMBL15961477 0.83 CYP4F2 (0.39) CYP4F2CYP4A11POLBALDH1A1TSHR
SCHEMBL11551475 0.83 ALDH1A1 (0.44) CYP4F2CYP4A11ALDH1A1TSHRKMT2A
SCHEMBL40349 0.83 CYP4F2 (0.51) CYP4F2CYP4A11CA12CA1CA2
SCHEMBL14257225 0.83 CYP4F2 (0.54) CYP4F2CYP4A11CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4171569-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF Council of Scientific & Industrial Research (IN) 2023-05-03 EP claimed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 WO claimed
CN-104610142-B 3-bishydrazide diphenylurea derivative, and preparation method and application of 3-bishydrazide diphenylurea derivative 青岛农业大学 2017-05-10 CN claimed
CN-104592059-B 3-acylhydrazone diphenylurea derivative and its preparation method and application 青岛农业大学 2016-07-06 CN claimed
CN-104610142-A 3-bishydrazide diphenylurea derivative, and preparation method and application of 3-bishydrazide diphenylurea derivative UNIV QINGDAO AGRICULTURAL 2015-05-13 CN claimed
CN-104592059-A 3-acylhydrazone diphenylurea derivatives as well as preparation method and applications thereof UNIV QINGDAO AGRICULTURAL 2015-05-06 CN claimed
EP-1754705-A2 Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders Genentech, Inc. (US) 2007-02-21 EP claimed
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 US disclosed
EP-4349609-A1 REVERSIBLY THERMOCHROMIC COMPOSITION, WRITING UTENSIL USING SAID REVERSIBLY THERMOCHROMIC COMPOSITION, AND TOY Mitsubishi Chemical Corporation (JP) 2024-04-10 EP disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
EP-4171569-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF Council of Scientific & Industrial Research (IN) 2023-05-03 EP disclosed
US-4451559-A 2-(SUBSTITUTED PHENYL-UREIDO) PHENOL-TYPE CYAN COUPLER KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1984-05-29 US disclosed
EP-0105991-A1 Silver halide photosensitive materials for color photography KONICA CORPORATION (JP) 1984-04-25 EP disclosed
EP-0058868-B1 DERIVATIVES OF TETRAHYDROPYRIMIDINON, PROCESS FOR THEIR PREPARATION AND HERBICIDES CONTAINING THOSE DERIVATIVES AS ACTIVE PRODUCTS NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1984-04-11 EP disclosed
US-4402731-A Herbicidally active novel substituted tetrahydropyrimidinones NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1983-09-06 US disclosed
EP-0067689-A1 Cyan couplers and colour photographic materials containing them KONICA CORPORATION (JP) 1982-12-22 EP disclosed
EP-0058868-A1 Derivatives of tetrahydropyrimidinon, process for their preparation and herbicides containing those derivatives as active products NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1982-09-01 EP disclosed
US-4285946-A ANOREXIGENIC AGENTS; TREATING DISTURBANCES OF THE METABOLISM OF LIPIDS HOECHST AKTIENGESELLSCHAFT (DE) 1981-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC CYP4F2 636/4885CYP4A11 370/4885CA12 4868/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 CYP4F2 1113/4885CYP4A11 853/4885CA12 4880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.